Aurotech Launches Drug Lifecycle Tracking Solution
The solution, DLTA, is built on a project-management platform overlaid with knowledge of drug development and FDA requirements.
Aurotech, Inc., an established management and IT consulting firm is entering the pharmaceutical market with the launch of its Drug Lifecycle Tracking Application (DLTA). DLTA is built on a project-management platform overlaid with knowledge of drug development and FDA requirements. The result is custom-mapped workflow management for the entire drug development lifecycle. Users have the ability to track, manage and monitor projects from centralized dashboards and in-system collaboration for hand-offs between teams.
For CROs, DLTA can be implemented to improve clinical trial workflows across large teams or projects. For a pharmaceutical organization, the solution can function as an end-to-end work management platform, to replace disparate systems.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
